Ending the global HIV/AIDS Pandemic: The critical role of an HIV vaccine

Clinical Infectious Diseases

Volumn 59, Issue , 2014, Pages S80-S84

  Fauci, Anthony S ^a   Folkers, Gregory K ^a   Marston, Hilary D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV prevention; HIV vaccine; Human immunodeficiency virus (HIV)

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PANDEMIC; PRIORITY JOURNAL; VACCINATION; HIV INFECTIONS;

AIDS VACCINES; HIV INFECTIONS; HUMANS; PANDEMICS; VACCINATION;

EID: 84926634007     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu420     Document Type: Article

References (25)

1. International AIDS Society. Turning the tide together: a declaration to end the AIDS epidemic, 2012. Available at: http://www.2endaids.org/wp-content/uploads/dc-declaration-Advert-Eng.pdf. Accessed 17 May 2014.
2. UN Joint Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 28 March 2014.
3. AIDS Vaccine Advocacy Coalition. The tipping point: understanding a crucial milestone in the AIDS response, 2013. Available at: http://www.thebody.com/content/72903/the-tipping-point-understanding-Acrucial-mileston.html. Accessed 6 June 2014.
4. Fauci AS, Marston HD. Ending AIDS-is an HIV vaccine necessary? N Engl J Med 2014; 370:495-8.
5. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
6. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012; 26:609-15.
7. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013; 10: e1001511.
8. Andrews CD, Spreen WR, Mohri H, et al. Long-Acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014; 343:1151-4.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
10. Rodger A, Bruun T, Cambiano V, et al. HIV Transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. In: Conference on Retroviruses and Opportunistic Infections (CROI 2014); 3-6 March; Boston, MA. Abstract 153LB.
11. Sgaier SK, Reed JB, Thomas A, Njeuhmeli E. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med 2014; 11:e1001641.
12. Kong X, Ssekasanvu J, Kigozi G, et al. Male circumcision coverage, knowledge, and attitudes after 4-years of program scale-up in Rakai, Uganda. AIDS Behav 2014; 18:880-4.
13. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr 2013; 3(suppl 2):S122-9.
14. Cohen JM, Smith DL, Cotter C, et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J 2012; 11:1-17.
15. Human Sciences Research Council. South African National HIV Prevalence, Incidence & Behaviour Survey, 2012. Available at: http://www. health-e.org.za/wp-content/uploads/2014/04/HRSC-2012.pdf. Accessed 4 April 2014.
16. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013; 31:3502-18.
17. Flynn NM, Forthal DN, Harro CD, et al. Placebo controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
18. Pitisuttithum P, Gilbert P, Gurwith M, et al; Bangkok Vaccine Evaluation Group. Randomized, double-blind placebo controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-71.
19. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009; 83:8300-14.
20. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
21. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296-302.
22. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-76.
23. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509:55-62.
24. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 2013; 13:693-701.
25. Hansen SG, Piatak M Jr., Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100-4.